Successful Outpatient Treatment of Legionella pneumophila Pneumonia With Lascufloxacin: A Case Report
Abstract
Legionella pneumophila is a significant cause of community-acquired pneumonia (CAP) and often necessitates hospitalization. Lascufloxacin (LSFX), a novel fluoroquinolone with high pulmonary penetration, has demonstrated efficacy in treating Legionella pneumonia in hospitalized patients. However, its use in an outpatient setting for Legionella pneumonia has not been previously documented, despite its favorable pharmacokinetics and safety profile. We present a 49-year-old man with a history of smoking and dyslipidemia who developed a high fever, headache, and malaise. In addition to the presence of relative bradycardia, chest imaging revealed right lower lobe pneumonia, and a urinary antigen test confirmed Legionella pneumophila infection. Despite this diagnosis, his condition remained stable (A-DROP score: 1), allowing for outpatient management. He was prescribed LSFX 75 mg/day for 10 days, with close monitoring via home pulse oximetry and scheduled frequent follow-up visits. His fever was resolved by day 3, and he fully recovered without complications or adverse effects. This is the first reported case of successful outpatient treatment of Legionella pneumonia with LSFX. The decision for outpatient therapy was based on the patient’s stable condition based on A-DROP (age, dehydration, respiratory failure, orientation disturbance, and low blood pressure) scoring, LSFX’s excellent bioavailability and pulmonary penetration, and its lack of renal dose adjustment requirements.…
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-Acinetobacter baumannii to fluoroquinolones
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.